Cargando…

Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study

DISCOVER is a 3-year observational study program of 15,983 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. We investigated the association between socioeconomic status and both the availability of a baseline glycated hemoglobin (HbA1c) measurement and poo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomes, Marília B., Tang, Fengming, Chen, Hungta, Cid-Ruzafa, Javier, Fenici, Peter, Khunti, Kamlesh, Rathmann, Wolfgang, Shestakova, Marina V., Surmont, Filip, Watada, Hirotaka, Medina, Jesús, Shimomura, Iichiro, Saraiva, Gabriela Luporini, Cooper, Andrew, Nicolucci, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072655/ https://www.ncbi.nlm.nih.gov/pubmed/35527995 http://dx.doi.org/10.3389/fendo.2022.831676

Ejemplares similares

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
por: Charbonnel, Bernard H., et al.
Publicado: (2022)

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019)

Type 2 diabetes and heart failure: insights from the global DISCOVER study
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study
por: Patel, Krishna K., et al.
Publicado: (2020)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study
por: Arnold, Suzanne V., et al.
Publicado: (2022)

The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control
por: Yoshii, Hidenori, et al.
Publicado: (2022)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study
por: Malik, Ali O., et al.
Publicado: (2022)

Changes of HbA1c variability after the switch to a longer‐acting insulin analog in people with type 1 diabetes
por: Watanabe, Hirotaka, et al.
Publicado: (2022)

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
por: Katakami, Naoto, et al.
Publicado: (2017)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
por: Wilding, John, et al.
Publicado: (2018)

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
por: Khunti, Kamlesh, et al.
Publicado: (2017)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study
por: Katakami, Naoto, et al.
Publicado: (2020)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
por: Takahara, Mitsuyoshi, et al.
Publicado: (2021)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

An Evaluation of Point-of-Care HbA1c, HbA1c Home Kits, and Glucose Management Indicator: Potential Solutions for Telehealth Glycemic Assessments
por: Zaharieva, Dessi P., et al.
Publicado: (2022)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
por: Ceriello, Antonio, et al.
Publicado: (2020)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c
por: Nomura, Kyoko, et al.
Publicado: (2011)

Relationship between HbA1c, fructosamine and clinical assessment of glycemic control in dogs
por: Norris, Olga, et al.
Publicado: (2022)

On the Association between Implant-Supported Prosthesis and Glycemic Control (HbA1c Values)
por: Masri, Daya, et al.
Publicado: (2022)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tlukfqalcth11s2b60e4jmdi0e